id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_mwnekthncnbihhzg4zttrl3hcy	Shadia Jalal	Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group	2010	4	.pdf	application/pdf	3055	339	59	single-agent activity in relapsed small cell lung cancer (SCLC). schedule evaluated as initial treatment in patients with metastatic breast cancer in which the combination resulted in an phase II study, which combined topotecan with bevacizumab.10 That trial included both chemosensitive and chemorefractory patients, was associated with more grade 3 to paclitaxel in patients with extensive-disease small-cell lung cancer: an Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 Paclitaxel Plus Bevacizumab in Patients with SCLC Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 Paclitaxel Plus Bevacizumab in Patients with SCLC Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group	./cache/work_mwnekthncnbihhzg4zttrl3hcy.pdf	./txt/work_mwnekthncnbihhzg4zttrl3hcy.txt